N-Acetyl Selank Amidate's evidence all comes from unmodified Selank

Is N-Acetyl Selank Amidate the same molecule as Selank?

N-Acetyl Selank Amidate is not Selank: it is Selank with an acetyl group added to the N-terminus and an amide group added to the C-terminus.

Selank is a synthetic heptapeptide built on the tuftsin backbone, developed in Russia as an anxiolytic. The two added groups are not cosmetic tweaks. Acetylation and amidation are classic peptide-stabilization strategies, used because they change how a peptide resists enzymatic degradation, how long it circulates, and how it distributes across tissues.

Changing those properties is the entire point of the modification. N-Acetyl Selank Amidate's pharmacokinetic profile, and potentially its receptor binding behavior, cannot be assumed identical to Selank's, even though the backbone sequence is closely related.

Has N-Acetyl Selank Amidate been studied at all?

N-Acetyl Selank Amidate has never been tested in a human or an animal; every study cited for it is a study of unmodified Selank.

Every citation attached to N-Acetyl Selank Amidate, on vendor pages, in forum posts, and in most existing articles, is a citation for Selank. Not one of the five Selank studies administered the acetylated, amidated form to a human being or an animal.

The Selank mechanism and trial results are real, but they belong to the parent compound. The Selank human trial evidence is reviewed separately.

How does Selank work?

Selank's proposed anxiolytic action centers on allosteric modulation of the GABA-A receptor.

In rats, intranasal Selank altered expression of 45 genes involved in GABAergic neurotransmission within an hour of dosing, including GABA receptor subunits, transporters, and ion channels, in frontal cortex tissue ^[4]. That is a preclinical, mechanistic finding. It shows a plausible pathway exists, not that the pathway produces a specific clinical effect in humans at a specific dose.

In humans, the strongest single piece of evidence is a randomized, placebo-controlled fMRI study in 52 healthy volunteers. Intranasal Selank altered resting-state functional connectivity between the right amygdala and right temporal cortex within 20 minutes of dosing ^[3].

The fMRI study is the first direct human neuroimaging evidence that Selank does something to a brain circuit involved in emotional processing, on a fast timescale consistent with nasal absorption. It is still a mechanistic snapshot in healthy volunteers, not a clinical outcome trial, and it used Selank, not the acetylated derivative.

Selank also has a historical connection to tuftsin and to enkephalinase-related immunomodulatory activity. That history is part of why Selank is sometimes framed as having "psychostimulant" or antiasthenic properties on top of anxiolysis, a pattern that shows up in the clinical trial data.

What did the Selank clinical trials show?

Two small Russian randomized trials of Selank, with 62 and 70 patients, found anxiolytic effects comparable to a benzodiazepine and fewer benzodiazepine side effects in combination ^[1]⁠^[2].

The first trial, in 62 patients with generalized anxiety disorder or neurasthenia, compared intranasal Selank with medazepam, a benzodiazepine. Selank performed comparably on anxiolytic efficacy and also showed antiasthenic and mild psychostimulant effects that the benzodiazepine arm did not produce ^[1].

That is a reasonable signal from a small, open-label-adjacent, single-country trial without independent replication. Its blinding falls short of the standard expected in a Western regulatory trial.

The second trial, in 70 anxiety-disorder patients, tested Selank as an add-on to phenazepam, another benzodiazepine, not as monotherapy. The combination reduced phenazepam's side effects (sedation, cognitive impairment, asthenia) and improved quality of life compared with phenazepam alone ^[2]. That result concerns Selank's ability to offset benzodiazepine side effects, a narrower and different claim from "Selank replaces a benzodiazepine."

How strong is the evidence behind N-Acetyl Selank Amidate?

N-Acetyl Selank Amidate's evidence rates grade D, limited: a plausible mechanism and thin clinical support, all from a different molecule.

Two rodent studies round out the mechanistic case for Selank. Besides the gene expression work ^[4], elevated plus maze data showed that Selank reduced stress-induced anxiety behavior in rats, with combined Selank plus diazepam performing best under sustained chronic stress ^[5].

The rat data reinforce the additive GABAergic modulation hypothesis. They do not resolve whether that effect translates to a stable oral or nasal human dose in a non-Russian population, using the acetylated derivative, over months of use.

The Selank evidence base is small, has limited independent replication, and does not establish broad clinical effectiveness. Grade D does not mean "no evidence" or "nothing here." The Selank and Semax evidence is reviewed separately.

What dose of N-Acetyl Selank Amidate do vendors suggest?

Vendor and forum sources suggest 250 to 500 micrograms of N-Acetyl Selank Amidate per administration, once or twice daily, but no dosing study of the modified compound exists.

Those protocols are typically intranasal or sublingual. The range seems to echo Selank study dosing, either the 300 mcg/kg rat dose ^[4] scaled down or the intranasal regimens from the human trials ^[1]⁠^[3], not anything established for N-Acetyl Selank Amidate itself. Any number attached to the modified compound is extrapolated, not derived.

Does sublingual N-Acetyl Selank Amidate work?

Sublingual N-Acetyl Selank Amidate has no precedent in any Selank study: the human trials and the rat gene expression study used intranasal dosing ^[1]⁠^[3]⁠^[4].

Route matters more than most write-ups acknowledge. People taking N-Acetyl Selank Amidate sublingually use a route with no direct precedent for either the parent or the modified compound. No study addresses absorption, onset, or even whether meaningful systemic exposure occurs sublingually versus nasally. The nasal route to the brain has its own explainer.

Is N-Acetyl Selank Amidate free of dependence and withdrawal?

No study shows that N-Acetyl Selank Amidate is free of dependence or withdrawal; the claim rests on short observation windows in small Selank trials.

None of the cited Selank studies was a dedicated long-term dependence-liability study, and no such study exists for the acetylated form most people buy. The widely circulated "no dependence, no withdrawal" framing applies to Selank, not to N-Acetyl Selank Amidate.

What side effects does N-Acetyl Selank Amidate cause?

Users of N-Acetyl Selank Amidate report nasal irritation, burning, congestion, headache, and mild fatigue or grogginess, none of it from systematically collected safety data.

Those reports come from users and vendor-adjacent sources. No formal human safety data exist for the acetylated, amidated form. Product purity and actual content from research-chemical vendors are unverified and vary.

What is still unknown about N-Acetyl Selank Amidate?

No study has dosed N-Acetyl Selank Amidate in a human being and measured anxiety, cognition, or anything else, and every other gap follows from that one:

• Pharmacokinetics. No data compare N-Acetyl Selank Amidate's pharmacokinetics with Selank's.
• Receptor affinity. Whether acetylation and amidation increase, decrease, or leave unchanged its GABA-A receptor affinity is unstudied.
• Long-term safety. Long-term safety, tolerance, interactions with other GABAergic compounds, and dependence liability specific to this molecule have no data at all.
• Product content. Purity and actual content from research-chemical vendors are unverified and vary.

Anyone using N-Acetyl Selank Amidate is, in a literal sense, running an uncontrolled n=1 experiment on a molecule that resembles, but is not, the one in the published record.